<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Retrophin, Inc.

    Retrophin, Inc.

    We are a biopharmaceutical company focused on developing our pipeline featuring sp...

    We are a biopharmaceutical company focused on d...

    Filing Type:    PU
    Principia Biopharma Inc.

    Principia Biopharma Inc.

    We are a late-stage biopharmaceutical company dedicated to bringing transformative...

    We are a late-stage biopharmaceutical company d...

    Filing Type:    PU
    Akebia Therapeutics, Inc.

    Akebia Therapeutics, Inc.

    We are a fully integrated biopharmaceutical company focused on the development and...

    We are a fully integrated biopharmaceutical com...

    Filing Type:    PU
    Avedro, Inc

    Avedro, Inc

    We are committed to advancing the treatment of eye conditions such as keratoconus ...

    We are committed to advancing the treatment of ...

    Filing Type:    PU
    Galapagos NV

    Galapagos NV

    Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...

    Galapagos develops therapies with proprietary, ...

    Filing Type:    PU
    Genprex, Inc.

    Genprex, Inc.

    Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in ...

    Genprex Inc is a U.S.-based clinical-stage gene...

    Filing Type:    PU
    Alpine Immune Sciences, Inc.

    Alpine Immune Sciences, Inc.

    Alpine is a development-stage specialty pharmaceutical company focused on discover...

    Alpine is a development-stage specialty pharmac...

    Filing Type:    PU
    BioLineRx Ltd.

    BioLineRx Ltd.

    BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. The C...

    BioLineRx is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Takeda Pharmaceutical Co., Ltd.

    Takeda Pharmaceutical Co., Ltd.

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-base...

    Takeda Pharmaceutical Company Limited (TSE:4502...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.